Inversago Pharma
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1100 René-lévesque Blvd West Ste 1110, M...Phone Number
(438) 300-2534Website
www.inversago.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inversago Pharma
Inversago Pharma is a clinical-stage biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.Explore more
Inversago Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inversago Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Inversago Pharma launches new products
Earning: See what the market has to say on Inversago Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Inversago Pharma
Check if Inversago Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Inversago Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Inversago Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Inversago Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inversago Pharma has new funding data
Recommended Actions
Reach out to Masked Content who joined Inversago Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Inversago Pharma
Compare insights from companies similar to Inversago Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Inversago Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Inversago Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Inversago Pharma.
Inversago Pharma financials insights
Gather financial insights about Inversago Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$7M
2020
Series B
$35M
2022
Series C
$70M
Inversago Pharma Tech Stack
A closer look at the technologies used by Inversago Pharma
Most Recent Scoops
Mergers & Acquisitions (M&A)
Event
Events, Spending/Investment
Funding
Event
Inversago Pharma News & Media
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
MONTREAL & SAN DIEGO--(BUSINESS WIRE)-- #CB1--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego. INV-202 is a potential first-in-class, peripherally-acting CB1r blocker, being developedInversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
MONTREAL, Québec--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor blockers to address complications associated with metabolic and fibrotic diseases, today announced that it will present data from the Phase 1b trial for INV-202, at the 83rd American Diabetes Association Scientific Sessions taking place on June 23-26, 2023, in San Diego, California. INV-202 is a potential first-in-class, peripheral CB1r blocker, being developedInversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C. In an oral presentation, Carolyn R. Morris, PhD, Facult
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Inversago Pharma
Sign Up For FreeTo access detailed company insights
Inversago Pharma is a clinical-stage biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.... Read More
